<DOC>
	<DOCNO>NCT01085032</DOCNO>
	<brief_summary>The study two-arm , parallel group , randomize , placebo-controlled , double blind trial , conduct four primary health care center Aleppo , Syria , test efficacy transdermal nicotine patch therapy vs. placebo patch therapy , deliver behavioral counseling , smoke cessation rate .</brief_summary>
	<brief_title>Nicotine Patch Trial Syrian Primary Care Settings</brief_title>
	<detailed_description>The study two-arm , parallel group , randomize , placebo-controlled , double blind trial , conduct four primary health care center Aleppo , Syria , test efficacy behavioral counseling without transdermal nicotine therapy long-term smoking cessation rate . The trial conduct four primary care clinic Aleppo , Syria sponsor private non governmental organization . Clinic physician train provide brief assessment patient 's smoking status motivation quit , refer appropriate patient cessation clinic within primary care center . Eligible interested smoker randomize receive behavioral cessation counsel + nicotine patch behavioral cessation counsel + placebo patch . Behavioral counseling deliver physician clinic . After eligibility determine description cessation program provide , write informed consent obtain . When literacy concern , consent form read subject mark form indicate consent . Participants provide baseline demographic data ( age , gender , ethnicity , residence , marital status , education , occupation , income ) , smoke relate information ( smoke history , level dependence , interest quitting , comorbidities ) , complete additional questionnaire ass quit self-efficacy , stage change , withdrawal symptom , depression/mood . Participants allocate one two treatment condition ( Arm A : behavioral counseling + nicotine patch v . Arm B : behavioral counseling + placebo patch ) use random permute block , stratify accord primary care center gender . Specific behavioral pharmacological intervention procedure follow : Participants Arm A receive active transdermal nicotine , participant Arm B receive placebo patch . Transdermal nicotine replacement select pharmacologic agent choice , base ease use , acceptability patient , favorable side effect contraindication profile , well research document efficacy ( Fiore et al. , 1994 ) . Additionally , pilot intervention work Syria indicate high degree acceptability patch potential smoking cessation intervention ( Asfar et al. , 2005 ) . In accordance clinical practice guideline U.S. ( Fiore et al. , 2000 ) , participant receive six week patch treatment , 24 hour dose , use step-down algorithm . Participants smoke great 10 cigarettes/day receive two week 21 mg patch , follow two week 14 mg patch , two week 7 mg patch . Participants smoke 5-9 cigarette per day receive four week 14 mg patch , follow two week 7 mg . Subjects arm receive three brief face-to-face counseling session five brief ( approximately 10 minute ) phone counsel call . Session 1 occurs 3-4 day schedule quit day focus prepare quit . Calls 1 2 occur day day quit day , respectively , focus survive first day non-smoker . Session 2 take place 7 day quit day emphasize provision social support , problem solving , cop withdrawal symptom negative emotion . The final session occur 14 day quit day emphasize relapse prevention cop skill train . An additional three phone call occur 10 , 30 , 45 day quit day provide social support , check progress , reinforce cop skill . Follow-up assessment occur 7 week , 6 month , 12 month post-cessation .</detailed_description>
	<mesh_term>Nicotine</mesh_term>
	<criteria>1865 year age smoking continuously least one year smoking 5 cigarette every day Reside catchment area one four primary care center diagnose generalized dermatology disease , liver failure , hyperthyroidism , pheochromocytoma current use psychotropic drug past year history drug alcohol abuse , unstable cardiovascular , psychiatric , debilitate disease base physician assessment . currently pregnant , lactating , intend become pregnant next 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Smoking Cessation</keyword>
	<keyword>Substance Withdrawal Syndrome</keyword>
	<keyword>Depression</keyword>
</DOC>